Dechra secures exclusive worldwide licensing deal

RNS Number : 4063L

Dechra Pharmaceuticals PLC

04 September 2012

 

Issued by TooleyStreet Communications

Date: Tuesday 4 September 2012

Dechra secures Exclusive Worldwide Licensing Deal

for the Treatment of Canine Dry Eye

Dechra Pharmaceuticals PLC ("Dechra") is pleased to announce that it has entered into an exclusive license agreement with SCYNEXIS^® Inc. for the development and commercialisation of SCY‑641, used for the treatment of canine keratoconjunctivitis sicca (KCS). 

Under the terms of the agreement, Dechra is granted worldwide animal health rights and will be responsible for the remaining clinical development and commercialisation of SCY-641 (SCYNEXIS retains the human health rights to the compound).

SCYNEXIS will receive an upfront fee from Dechra and is eligible to receive further payments based on development milestones, as well as royalties on product sales. 

SCY-641, a cyclosporine derivative, is the first partnered compound from the SCYNEXIS proprietary cyclophilin inhibitor platform, which includes SCY‑635, a clinical candidate for the treatment of Hepatitis C (HCV).

Commenting on the partnership, Ian Page, Chief Executive, Dechra said:

"We are delighted to have reached an agreement with SCYNEXIS and look forward to a successful partnership and bringing SCY-641 to market.  The worldwide agreementsubstantially strengthens our novel product development pipeline.  The ophthalmic market is a key therapeutic sector for Dechra; the application of SCY-641 in the animal health market offers significantly improved clinical treatment of dry eye in animals and an excellent commercial opportunity."

Michael Peel, PhD, Executive Director for SCYNEXIS Discovery Research commented:

"This is the first partnership for SCYNEXIS Cyclophilin Platform and Dechra is the ideal partner for SCY-641 as they have a strong presence in animal health and a history of successful new product introductions.  We believe that this novel compound has the potential to offer a major advance in the treatment of dry eye in both animal and human health."

Enquiries:
Dechra Pharmaceuticals PLC  Sector: Premium Listing (Pharmaceuticals): DPH		TooleyStreet Communications Limited
Ian Page, Chief Executive		Fiona Tooley, Director
Simon Evans, Group Finance Director		Graeme Cull, Consultant
Mobile:	[phone] (IP) or [phone] (SE)	Mobile:	[phone] (FMT) or [phone](GC)
Office:	[phone]	Office:	[phone]
www.dechra.com       [e-mail]

Dechra and the Dechra 'D' logo are registered trademarks of Dechra Pharmaceuticals PLC.

About SCYNEXIS

SCYNEXIS delivers innovative solutions to solve the toughest problems in drug discovery and development for our pharmaceutical, global health and life science partners. We have successfully delivered preclinical and clinical drug candidates to our customers across all major therapeutic indications and have developed our own proprietary cyclophilin inhibitor programs for the treatment of a broad range of diseases, including HCV and inflammation. www.scynexis.com.

Contact: Alissa Maupin, Marketing & Communications Manager

SCYNEXIS, Inc.            

[e-mail]                                      

+1 919.206.7246

 

END

 

 

STRVXLFBLKFBBBV